NuPathe Inc. to Report First Quarter 2011 Results and Hold Conference Call on Tuesday, May 10, 2011

CONSHOHOCKEN, PA--(Marketwire - May 03, 2011) - NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, will report first quarter 2011 results on Tuesday, May 10, 2011 before the open of the U.S. financial markets. NuPathe will also host a conference call at 8:30 a.m. EDT on the same day to discuss the first quarter 2011 financial results and recent operational highlights. A question and answer session will follow NuPathe’s remarks.

To participate on the live call, please dial 877-780-3379 (domestic) or +1-719-325-2170 (international), and provide the participant passcode 9225975 five to ten minutes ahead of the start of the call. A replay of the call will be available for 90 days within a few hours after the call ends. Investors may listen to the replay of the call by dialing 888-203-1112 (domestic) or +1-719-457-0820 (international), with the passcode 9225975.

A live audio webcast of the call will be also available via the “Investor Relations” page of the NuPathe website, www.nupathe.com. Please log on through NuPathe’s website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will be archived on NuPathe’s website for 90 days following the call.

About NuPathe
NuPathe Inc. (www.nupathe.com) is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe’s lead product candidate, Zelrix, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to Zelrix, NuPathe has two proprietary product candidates in preclinical development: NP201 for the continuous symptomatic treatment of Parkinson’s disease, and NP202 for the long-term treatment of schizophrenia and bipolar disorder.